List of Chapters/Sections(Table Of Content)
1 Study Coverage
1.1 Novel Oral AntiCoagulants (NOAC) Product Introduction
1.2 Global Novel Oral AntiCoagulants (NOAC) Outlook 2017 VS 2022 VS 2028
1.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in US$ Million for the Year 2017-2028
1.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume for the Year 2017-2028
1.3 United States Novel Oral AntiCoagulants (NOAC) Outlook 2017 VS 2022 VS 2028
1.3.1 United States Novel Oral AntiCoagulants (NOAC) Sales in US$ Million for the Year 2017-2028
1.3.2 United States Novel Oral AntiCoagulants (NOAC) Sales in Volume for the Year 2017-2028
1.4 Novel Oral AntiCoagulants (NOAC) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Novel Oral AntiCoagulants (NOAC) in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Novel Oral AntiCoagulants (NOAC) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Novel Oral AntiCoagulants (NOAC) Market Dynamics
1.5.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
1.5.2 Novel Oral AntiCoagulants (NOAC) Market Drivers
1.5.3 Novel Oral AntiCoagulants (NOAC) Market Challenges
1.5.4 Novel Oral AntiCoagulants (NOAC) Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Novel Oral AntiCoagulants (NOAC) Market Segment by Type
2.1.1 Direct Thrombin Inhibitors
2.1.2 Direct Factor Xa Inhibitors
2.2 Global Novel Oral AntiCoagulants (NOAC) Market Size by Type
2.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Novel Oral AntiCoagulants (NOAC) Market Size by Type
2.3.1 United States Novel Oral AntiCoagulants (NOAC) Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Novel Oral AntiCoagulants (NOAC) Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Novel Oral AntiCoagulants (NOAC) Market Segment by Application
3.1.1 Deep Vein Thrombosis (DVT)
3.1.2 Pulmonary Embolism
3.1.3 Acute Coronary Syndrome
3.1.4 Hemodialysis
3.1.5 Others
3.2 Global Novel Oral AntiCoagulants (NOAC) Market Size by Application
3.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Novel Oral AntiCoagulants (NOAC) Market Size by Application
3.3.1 United States Novel Oral AntiCoagulants (NOAC) Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Novel Oral AntiCoagulants (NOAC) Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Novel Oral AntiCoagulants (NOAC) Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Novel Oral AntiCoagulants (NOAC) Competitor Landscape by Company
4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Company
4.1.1 Top Global Novel Oral AntiCoagulants (NOAC) Manufacturers Ranked by Revenue (2021)
4.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturer (2017-2022)
4.1.3 Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturer (2017-2022)
4.1.4 Global Novel Oral AntiCoagulants (NOAC) Price by Manufacturer (2017-2022)
4.2 Global Novel Oral AntiCoagulants (NOAC) Concentration Ratio (CR)
4.2.1 Novel Oral AntiCoagulants (NOAC) Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Novel Oral AntiCoagulants (NOAC) in 2021
4.2.3 Global Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Novel Oral AntiCoagulants (NOAC) Manufacturing Base Distribution, Product Type
4.3.1 Global Novel Oral AntiCoagulants (NOAC) Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Novel Oral AntiCoagulants (NOAC) Product Type
4.3.3 Date of International Manufacturers Enter into Novel Oral AntiCoagulants (NOAC) Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Novel Oral AntiCoagulants (NOAC) Market Size by Company
4.5.1 Top Novel Oral AntiCoagulants (NOAC) Players in United States, Ranked by Revenue (2021)
4.5.2 United States Novel Oral AntiCoagulants (NOAC) Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Novel Oral AntiCoagulants (NOAC) Sales by Players (2020, 2021 & 2022)
5 Global Novel Oral AntiCoagulants (NOAC) Market Size by Region
5.1 Global Novel Oral AntiCoagulants (NOAC) Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Novel Oral AntiCoagulants (NOAC) Market Size in Volume by Region (2017-2028)
5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume by Region: 2017-2022
5.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume Forecast by Region (2023-2028)
5.3 Global Novel Oral AntiCoagulants (NOAC) Market Size in Value by Region (2017-2028)
5.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region: 2017-2022
5.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Novel Oral AntiCoagulants (NOAC) Market Size YoY Growth 2017-2028
6.1.2 North America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Novel Oral AntiCoagulants (NOAC) Market Size YoY Growth 2017-2028
6.3.2 Europe Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Novel Oral AntiCoagulants (NOAC) Market Size YoY Growth 2017-2028
6.4.2 Latin America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Corporation Information
7.1.2 Johnson & Johnson Description and Business Overview
7.1.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Products Offered
7.1.5 Johnson & Johnson Recent Development
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Corporation Information
7.2.2 Bristol-Myers Squibb Description and Business Overview
7.2.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Products Offered
7.2.5 Bristol-Myers Squibb Recent Development
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim Corporation Information
7.3.2 Boehringer Ingelheim Description and Business Overview
7.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Products Offered
7.3.5 Boehringer Ingelheim Recent Development
7.4 Sanofi
7.4.1 Sanofi Corporation Information
7.4.2 Sanofi Description and Business Overview
7.4.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Sanofi Novel Oral AntiCoagulants (NOAC) Products Offered
7.4.5 Sanofi Recent Development
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Corporation Information
7.5.2 Daiichi Sankyo Description and Business Overview
7.5.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Products Offered
7.5.5 Daiichi Sankyo Recent Development
7.6 Armatheon
7.6.1 Armatheon Corporation Information
7.6.2 Armatheon Description and Business Overview
7.6.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Armatheon Novel Oral AntiCoagulants (NOAC) Products Offered
7.6.5 Armatheon Recent Development
7.7 Aspen
7.7.1 Aspen Corporation Information
7.7.2 Aspen Description and Business Overview
7.7.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Aspen Novel Oral AntiCoagulants (NOAC) Products Offered
7.7.5 Aspen Recent Development
7.8 AstraZeneca
7.8.1 AstraZeneca Corporation Information
7.8.2 AstraZeneca Description and Business Overview
7.8.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.8.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Products Offered
7.8.5 AstraZeneca Recent Development
7.9 Bayer
7.9.1 Bayer Corporation Information
7.9.2 Bayer Description and Business Overview
7.9.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Bayer Novel Oral AntiCoagulants (NOAC) Products Offered
7.9.5 Bayer Recent Development
7.10 Cellceutix
7.10.1 Cellceutix Corporation Information
7.10.2 Cellceutix Description and Business Overview
7.10.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Products Offered
7.10.5 Cellceutix Recent Development
7.11 Cosmo Pharmaceuticals
7.11.1 Cosmo Pharmaceuticals Corporation Information
7.11.2 Cosmo Pharmaceuticals Description and Business Overview
7.11.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Products Offered
7.11.5 Cosmo Pharmaceuticals Recent Development
7.12 CSL Behring
7.12.1 CSL Behring Corporation Information
7.12.2 CSL Behring Description and Business Overview
7.12.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.12.4 CSL Behring Products Offered
7.12.5 CSL Behring Recent Development
7.13 Eisai
7.13.1 Eisai Corporation Information
7.13.2 Eisai Description and Business Overview
7.13.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Eisai Products Offered
7.13.5 Eisai Recent Development
7.14 GSK
7.14.1 GSK Corporation Information
7.14.2 GSK Description and Business Overview
7.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.14.4 GSK Products Offered
7.14.5 GSK Recent Development
7.15 Marathon Pharmaceuticals
7.15.1 Marathon Pharmaceuticals Corporation Information
7.15.2 Marathon Pharmaceuticals Description and Business Overview
7.15.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Marathon Pharmaceuticals Products Offered
7.15.5 Marathon Pharmaceuticals Recent Development
7.16 Ockham Biotech
7.16.1 Ockham Biotech Corporation Information
7.16.2 Ockham Biotech Description and Business Overview
7.16.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Ockham Biotech Products Offered
7.16.5 Ockham Biotech Recent Development
7.17 Perosphere
7.17.1 Perosphere Corporation Information
7.17.2 Perosphere Description and Business Overview
7.17.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Perosphere Products Offered
7.17.5 Perosphere Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Novel Oral AntiCoagulants (NOAC) Industry Chain Analysis
8.2 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
8.3 Novel Oral AntiCoagulants (NOAC) Production Mode & Process
8.4 Novel Oral AntiCoagulants (NOAC) Sales and Marketing
8.4.1 Novel Oral AntiCoagulants (NOAC) Sales Channels
8.4.2 Novel Oral AntiCoagulants (NOAC) Distributors
8.5 Novel Oral AntiCoagulants (NOAC) Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
